A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/557 (2006.01) A61K 49/00 (2006.01) A61P 29/00 (2006.01)
Patent
CA 2615917
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF.alpha.)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1 to 10 nM, the LXA4 and ATL analogs each inhibited TNF.alpha.-stimulated superoxide anion generation and IL-1.beta. release by human PMN.
Les effets de la lipoxine A4 (LXA4) et des lipoxines induites par l'aspirine (ATL) ont été étudiés à l'aide de réponses induites chez le neutrophile par le TNF alpha (tumor necrosis factor) in vitro et in vivo en présence d'analogues métaboliquement stables de LX. A des concentrations aussi faibles que 1 à 10 nM, les analogues de la LXA4 et des ATL ont chacun inhibé la production d'anion superoxyde stimulée par le TNF alpha et la libération d'IL-1 bêta par des PMN humains.
Brigham And Women's Hospital
Riches Mckenzie & Herbert Llp
LandOfFree
Use of lipoxin compounds for inhibiting of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of lipoxin compounds for inhibiting of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lipoxin compounds for inhibiting of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1983912